134 results
Page 4 of 7
8-K
EX-99.1
ucifagch
7 May 20
Intra-cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update
7:42am
8-K
EX-99.1
3hszfgzj epoj
23 Mar 20
Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia
7:52am
8-K
EX-99.1
vsboxs1f5o
2 Mar 20
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2019 Financial Results and Provides Corporate Update
7:43am
424B5
mjxkdjgsi1aw7qi je
8 Jan 20
Prospectus supplement for primary offering
5:06pm
8-K
EX-99.3
z0jg4qs
6 Jan 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4:52pm
424B5
c9zlxfptx0l
6 Jan 20
Prospectus supplement for primary offering
4:42pm
S-3ASR
EX-4.11
b2sn3316j p26ue0x
6 Jan 20
Automatic shelf registration
4:02pm
S-3ASR
ebibrmxfvcp
6 Jan 20
Automatic shelf registration
4:02pm
S-3ASR
EX-4.10
y64zt7d1oyg147l4vi
6 Jan 20
Automatic shelf registration
4:02pm
8-K
EX-99.1
5n0nh uh63roj4
23 Dec 19
FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults
8:15am